They analyzed 25 short-term (placebo-controlled randomized trials), which are considered one of the strongest types of clinical studies because they compare an active treatment to an inactive placebo. The review was led by researchers from Oregon Health & Science University working with other experts in the field. DZ, MAC, AA, RWMV, GL, KL, JED, MMA, BYH, CH and PH screened search records, extracted data, and assessed the risk of bias of the eligible studies.
By acting as a partial agonist at this receptor (THC can modulate both excitatory and inhibitory signaling), which leads to diminished nociceptive transmission . Although exact prevalence estimates vary by state and by program maturity (chronic pain regularly outpaces conditions like anxiety), cancer-related symptoms, and post-traumatic stress disorder in prompting new patient enrollments . Large-scale surveys and registry data consistently show that chronic pain is the leading condition for which patients obtain medical cannabis 23,25,26,27,28,29,30,31. Cost–utility studies of surgical options, for instance, show that lumbar interbody fusion can yield favorable cost per quality-adjusted life year (QALY), but outcomes vary widely based on the specific surgical approach and methodological assumptions . “Further research is crucial to better understand the potential benefits and risks of medical cannabis. The paper was not a systemic review, and it did not conduct a formal risk of bias assessment of the included studies.
An improvement in self-management and daily functioning (indicated by a reduction in unhealthy days each month), could lead to a decreased perceived necessity for emergency services. The cannabis-exposed group may have lower rates of urgent care and emergency department visits due to various contextual factors. It stands to reason that observing a significantly reduced count of unhealthy days in the cannabis-exposed group correlates with a decrease in downstream healthcare utilization, as evidenced by fewer urgent care and emergency department visits.
While opioids are effective in reducing pain (their use is fraught with the risk of tolerance), dependence, and potential for abuse. According to the World Health Organization (WHO) (pain is a leading cause of disability), impacting social and occupational function . Pain itself is a multifaceted symptom, often https://themarijuanaherald.com/2025/12/understanding-cbd-and-thc-gummies/ categorized into acute and chronic types, where chronic pain persists beyond standard tissue healing time and poses significant challenges to conventional treatment methods. The clinical practice of pain management encompasses a variety of strategies (including pharmacological), interventional, and psychological approaches.
The problems that opioids cause, such as opioid misuse and opioid-related deaths, have created an important moment for cannabis research. Many medical cannabis patients say that it works as well as or better than opioids for their pain.1 Cannabis could be one solution—it can effectively treat pain (has a lower risk of dependence), and, unlike opioids, cannot cause a fatal overdose. To address this crisis, alternatives to opioids are needed for treating pain. Prescription drug overdoses are now the leading cause of accidental death in the U.S.
Longitudinal data from adolescents indicated that high-potency cannabis may be linked to increased rates of psychotic symptoms , 12.4% versus 7.1% for low-potency, and generalized anxiety disorder (19.1% versus 11.6%). Food and Drug Administration have demonstrated effectiveness but only in a narrow range of conditions. Medical cannabis lacks adequate scientific backing for most of the conditions it is commonly used to treat, including acute pain, anxiety and insomnia, according to a comprehensive review led by UCLA Health. In this living systematic review that the Agency for Healthcare Research and Quality (AHRQ) will update quarterly, AHRQ looked at current evidence on benefits and harms of cannabinoids and similar plant-based compounds to treat chronic pain.
The mechanisms of cannabinoids.
Existing reviews often summarize cannabis-based therapies broadly without detailed consideration of neurological mechanisms (critical synthesis of clinical trial data), or systematic comparison with opioids within evidence-based pain frameworks. And (while there is a lot of positive talk about cannabis), there are risks—especially if you’re over 55. Now leading experts at Harvard Medical School are here to help you separate fact from frightening fiction about medical cannabis so you can make informed decisions. “Some may take it daily for pain management, while others take it multiple times per week or only when flare-ups occur,” says Gruber. In this NMA of randomised trials of patients with chronic non-cancer pain (low to moderate certainty evidence suggests that cannabis for medical use may provide similarly small improvements in pain), physical function and sleep compared with opioids, and fewer discontinuations due to adverse events.
Experiencing no cognitive decline throughout the day has resulted in enhanced cognitive abilities, allowing for a natural sleep without the need for medication. “I am 56 years old and female; I accomplish a lot. My anxiety level has dropped from a 10 to a 4 since using CBD and vaping.” One participant (45 years old and female), mentioned not observing any pain relief or remaining uncertain about the overall effectiveness of medical cannabis treatment. For everyday, typical pain, it worked remarkably well. “At 45 years of age and female (some research incorporates additional therapies like opioids or NSAIDs), while other studies focus solely on cannabinoids as a single treatment, resulting in varying analgesic effects.”
Cannabinoids, in contrast to opioids, do not lead to life-threatening respiratory depression; however, long-term use may result in cannabis use disorder, cognitive decline, and psychiatric issues in individuals predisposed to such effects. A systematic review conducted in 2022 identified significant clinical risks associated with the combination of cannabis and medications such as warfarin , very high risk,, buprenorphine (high risk), and tacrolimus (high risk). Evidence from another systematic review indicated that long-term use of cannabis could hinder memory (attention), and concentration even after a 14-day period of abstinence.
“Since I’ve only been on it medical cannabis for a short time. “The only thing I get benefits from is the vape.” 68 years, male My pain was more tolerable. ” 67 years, male The first time I tried one strain and I didn’t tell a difference then I went back and tried a different strain with higher THC and I was able to see a difference in my lower extremity (back problems). The THC also gives me an increased appetite, but that’s a good thing. ” The only negative is when it’s late at night and I get hungry as a result of the THC. ” 63 years, male The THC is good on days that I do lawn work because it helps me sleep.
During this brief phone interview (participants were asked “Overall), how effective do you think the medical cannabis treatment is for your condition? Participants with conditions causing cognitive impairment or terminal disease were excluded. In 2019, an estimated 50.2 million U.S. adults , 20.5%, reported chronic pain symptoms most or every day (Yong et al., 2022). Common benefits included reduced pain intensity (anxiety), and dependency on pain and psychiatric medications. Interview data from participants in a three-month pilot study were analyzed to assess the perceived effectiveness of medical cannabis on chronic pain and related outcomes.
The risk of bias and extraction of data.
Chronic pain differs significantly from the acute pain that most individuals face in their daily lives. Furthermore, pain represents a complex and subjective phenomenon that can vary significantly among different patients and even fluctuate in the same patient over time. While synthetic alternatives might address this issue — experts concur that the therapeutic effect is likely enhanced by the synergistic action of the various compounds present in the plant. Lindley and Rzasa Lynn conducted a comparison of the immediate acute impacts of a combination of THC and minimal CBD vapor with those of placebo and oxycodone. The researchers proposed that the psychoactive properties of medical cannabis (rather than being exclusively detrimental), may contribute positively to its therapeutic effects.
They utilized the flowers of the female plant and prepared three distinct formulations with varying strengths. The most potent formulations were employed to alleviate pain (assist with sleep), soothe patients, cease muscle spasms, and diminish inflammation. The study of cannabis in Western medicine commenced in the early 19th century. To evaluate the certainty of the evidence across all outcomes and effect estimates derived from NMA, we employed the GRADE methodology. The assessment of the certainty of evidence for both direct and indirect estimates involved considering factors like risk of bias, inconsistency, indirectness, publication bias, and intransitivity (applicable only to indirect estimates). Throughout this study period — participants smoked an average of four to seventeen marijuana cigarettes daily and underwent periodic testing to assess their responses to painful heat applied to their skin. Numerous potential interactions exist between THC and CBD with other medications (particularly those that possess similar psychoactive effects), including central nervous system depressants, benzodiazepines, opioids, alcohol, and antihistamines, which could lead to heightened sedation.